Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc has good value characteristics. Jazz Pharmaceuticals plc is not very popular among insiders. Jazz Pharmaceuticals plc is a mediocre stock to choose.
Log in to see more information.
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the ide...

News

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Headlands Technologies LLC
Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Purchased by Headlands Technologies LLC

Zolmax Headlands Technologies LLC boosted its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 96.3% in the 2nd quarter, according to its most recent disclosure with the Securities and...\n more…

Victory Capital Management Inc. Increases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)
Victory Capital Management Inc. Increases Position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Zolmax Victory Capital Management Inc. lifted its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 42.7% in the second quarter, HoldingsChannel.com reports. The fund owned...\n more…

Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Needham & Company LLC
Jazz Pharmaceuticals (NASDAQ:JAZZ) Rating Reiterated by Needham & Company LLC

Zolmax Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)s stock had its "buy" rating reiterated by Needham Company LLC in a research note issued to investors on Tuesday, Benzinga reports...\n more…

Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Needham & Company LLC Reiterates Buy Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Ticker Report Needham Company LLC reaffirmed their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ - Free Report) in a report published on Tuesday, Benzinga reports. Needham Company LLC...\n more…

Cantor Fitzgerald Reiterates "Overweight" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Cantor Fitzgerald Reiterates "Overweight" Rating for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Ticker Report Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)s stock had its "overweight" rating reiterated by investment analysts at Cantor Fitzgerald in a research note issued on Monday, Benzinga...\n more…

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Reaffirmed by Cantor Fitzgerald
Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Rating Reaffirmed by Cantor Fitzgerald

Zolmax Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report)s stock had its "overweight" rating reiterated by analysts at Cantor Fitzgerald in a research report issued to clients and investors on...\n more…